This progress is perhaps most notable for personalized treatment of channelopathies such as long QT syndrome due to mutations in KCNH2 that disrupt intracellular trafficking of the hERG potassium channel Kv11.1 (LQT2). The gene discussed is KCNH2; the disease is channelopathy.